Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229453208> ?p ?o ?g. }
- W4229453208 endingPage "153" @default.
- W4229453208 startingPage "142" @default.
- W4229453208 abstract "Immune checkpoint inhibitors, such as programmed cell death ligand 1 inhibitors pembrolizumab, nivolumab, atezolizumab, and avelumab, are used to treat patients with advanced urothelial carcinoma (UC). Based on data from the phase 3 JAVELIN Bladder 100 trial, avelumab first-line (1L) maintenance is now considered the standard-of-care treatment for patients with locally advanced or metastatic UC who responded or experienced disease stabilization after 1L platinum-containing chemotherapy, and it is the only category 1 preferred checkpoint inhibitor maintenance option in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for patients with cisplatin-eligible and cisplatin-ineligible locally advanced or metastatic UC. This article reviews key considerations related to avelumab 1L maintenance therapy that infusion nurses should be familiar with, including dosing, administration, and immune-related adverse event recognition and management, to ensure safe and appropriate use of this important and impactful therapy." @default.
- W4229453208 created "2022-05-11" @default.
- W4229453208 creator A5008174951 @default.
- W4229453208 creator A5018347340 @default.
- W4229453208 creator A5018631210 @default.
- W4229453208 creator A5024530529 @default.
- W4229453208 creator A5039020134 @default.
- W4229453208 creator A5045335522 @default.
- W4229453208 creator A5065001553 @default.
- W4229453208 creator A5086068122 @default.
- W4229453208 date "2022-05-01" @default.
- W4229453208 modified "2023-09-27" @default.
- W4229453208 title "Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses" @default.
- W4229453208 cites W1820495241 @default.
- W4229453208 cites W1986382801 @default.
- W4229453208 cites W2071069178 @default.
- W4229453208 cites W2101562875 @default.
- W4229453208 cites W2103257412 @default.
- W4229453208 cites W2129958862 @default.
- W4229453208 cites W2148562299 @default.
- W4229453208 cites W2152762320 @default.
- W4229453208 cites W2153841693 @default.
- W4229453208 cites W2210453860 @default.
- W4229453208 cites W2287918349 @default.
- W4229453208 cites W2304807567 @default.
- W4229453208 cites W2334822541 @default.
- W4229453208 cites W2768429453 @default.
- W4229453208 cites W2774605139 @default.
- W4229453208 cites W2789502254 @default.
- W4229453208 cites W2793892124 @default.
- W4229453208 cites W2795139701 @default.
- W4229453208 cites W2799419532 @default.
- W4229453208 cites W2800509387 @default.
- W4229453208 cites W2889646458 @default.
- W4229453208 cites W2891365914 @default.
- W4229453208 cites W2902391954 @default.
- W4229453208 cites W2933397876 @default.
- W4229453208 cites W2973437854 @default.
- W4229453208 cites W2976156055 @default.
- W4229453208 cites W2983476233 @default.
- W4229453208 cites W3007123110 @default.
- W4229453208 cites W3087464965 @default.
- W4229453208 cites W3087874197 @default.
- W4229453208 cites W3088736135 @default.
- W4229453208 cites W3115068211 @default.
- W4229453208 cites W3133853946 @default.
- W4229453208 cites W3137251658 @default.
- W4229453208 cites W3171334864 @default.
- W4229453208 cites W4313635027 @default.
- W4229453208 doi "https://doi.org/10.1097/nan.0000000000000465" @default.
- W4229453208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35537002" @default.
- W4229453208 hasPublicationYear "2022" @default.
- W4229453208 type Work @default.
- W4229453208 citedByCount "0" @default.
- W4229453208 crossrefType "journal-article" @default.
- W4229453208 hasAuthorship W4229453208A5008174951 @default.
- W4229453208 hasAuthorship W4229453208A5018347340 @default.
- W4229453208 hasAuthorship W4229453208A5018631210 @default.
- W4229453208 hasAuthorship W4229453208A5024530529 @default.
- W4229453208 hasAuthorship W4229453208A5039020134 @default.
- W4229453208 hasAuthorship W4229453208A5045335522 @default.
- W4229453208 hasAuthorship W4229453208A5065001553 @default.
- W4229453208 hasAuthorship W4229453208A5086068122 @default.
- W4229453208 hasBestOaLocation W42294532081 @default.
- W4229453208 hasConcept C121608353 @default.
- W4229453208 hasConcept C126322002 @default.
- W4229453208 hasConcept C143998085 @default.
- W4229453208 hasConcept C177713679 @default.
- W4229453208 hasConcept C2775949291 @default.
- W4229453208 hasConcept C2776694085 @default.
- W4229453208 hasConcept C2777381376 @default.
- W4229453208 hasConcept C2777701055 @default.
- W4229453208 hasConcept C2778239845 @default.
- W4229453208 hasConcept C2778283404 @default.
- W4229453208 hasConcept C2780030458 @default.
- W4229453208 hasConcept C2780057760 @default.
- W4229453208 hasConcept C2780352672 @default.
- W4229453208 hasConcept C2911057145 @default.
- W4229453208 hasConcept C3019882237 @default.
- W4229453208 hasConcept C71924100 @default.
- W4229453208 hasConceptScore W4229453208C121608353 @default.
- W4229453208 hasConceptScore W4229453208C126322002 @default.
- W4229453208 hasConceptScore W4229453208C143998085 @default.
- W4229453208 hasConceptScore W4229453208C177713679 @default.
- W4229453208 hasConceptScore W4229453208C2775949291 @default.
- W4229453208 hasConceptScore W4229453208C2776694085 @default.
- W4229453208 hasConceptScore W4229453208C2777381376 @default.
- W4229453208 hasConceptScore W4229453208C2777701055 @default.
- W4229453208 hasConceptScore W4229453208C2778239845 @default.
- W4229453208 hasConceptScore W4229453208C2778283404 @default.
- W4229453208 hasConceptScore W4229453208C2780030458 @default.
- W4229453208 hasConceptScore W4229453208C2780057760 @default.
- W4229453208 hasConceptScore W4229453208C2780352672 @default.
- W4229453208 hasConceptScore W4229453208C2911057145 @default.
- W4229453208 hasConceptScore W4229453208C3019882237 @default.
- W4229453208 hasConceptScore W4229453208C71924100 @default.
- W4229453208 hasIssue "3" @default.
- W4229453208 hasLocation W42294532081 @default.